Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia Disorder
NCT06823752Phase 2Recruiting
- Sponsor
- Woolcock Institute of Medical Research
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lemborexant in Insomnia, sponsored by Woolcock Institute of Medical Research. Started May 2025; status: recruiting.
02
Drugs
lemborexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT06823752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06823752.